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ABSTRACT 
Background: ATR-Chk1 signalling network is critical for genomic stability. ATR-Chk1 may 
be deregulated in breast cancer and have prognostic, predictive and therapeutic significance. 
Patients and methods: We investigated ATR and phosphorylated CHK1Ser345 protein 
(pChk1) expression in 1712 breast cancers (Nottingham Tenovus series).  ATR and Chk1 
mRNA were evaluated in 1950 breast cancers (METABRIC cohort). Pre-clinically, biological 
consequences of ATR gene knockdown or ATR inhibition by small molecule inhibitor (VE-
821) were investigated in MCF-7 and MDA-MB-231 breast cancer cell lines and in non-
tumorigenic breast epithelial cells (MCF10A).   
Results:  High ATR and high cytoplasmic pChk1 expression was significantly associated 
with higher tumour stage, higher mitotic index, pleomorphism and lymphovascular invasion.  
In univariate analysis, high ATR and high cytoplasmic pChk1 protein expression was 
associated with shorter breast cancer specific survival (BCSS).  In multivariate analysis, high 
ATR remains an independent predictor of adverse outcome. At the mRNA level, high Chk1 
remains associated with aggressive phenotypes including lymph node positivity, high grade, 
Her-2 overexpression, triple-negative phenotype and molecular classes associated with 
aggressive behaviour and shorter survival..  Pre-clinically, Chk1 phosphorylation at serine 
345 following replication stress (induced by gemcitabine or hydroxyurea treatment) was 
impaired in ATR knockdown and in VE-821 treated breast cancer cells. Doxycycline 
inducible knockdown of ATR suppressed growth, which was restored when ATR was re-
expressed. Similarly, VE-821 treatment resulted in a dose dependent suppression of cancer 
cell growth and survival (MCF7 and MDA-MB-231) but had no effect on non-tumorigenic 
breast epithelial cells (MCF10A).  
Conclusions: We provides evidence that ATR and Chk1 are promising biomarkers and 
rational drug target for personalized therapy in breast cancer. 
INTRODUCTION 
Ataxia telangiectasia mutated and Rad3 related protein (ATR), a serine threonine kinase 
belonging to the PIKK family (phosphoinositide 3-kinase-like-family of protein kinase), is a 
key regulator of genomic integrity. ATR is activated by single stranded (ss)-double stranded 
(ds) DNA junctions generated at stalled replication forks that frequently occur at sites of 
DNA damage.  Activated ATR in turn phosphorylates Chk1 at Ser 345 and Ser 317, as well as 
several other target proteins involved in homologous recombination repair and DNA cross 
link repair. Phosphorylation of Chk1 at Ser 345  (pChk1) leads to its activation which not only 
promotes further autophosphorylation at Ser 296, but also results in phosphorylation and 
inactivation of Cdc25A and Cdc25c. Whereas Cdc25A activates S-phase progression, 
Cdc25C through CDK1 (Cdc2) regulates mitotic entry. In addition, Chk1 also targets many 
other proteins involved in cell cycle regulation and DNA repair.  As a consequence of the 
considerable cross talk, ATR-Chk1 activation ultimately results in arrest of cell cycle 
progression allowing sufficient time for DNA repair to be completed for the maintenance of 
genomic integrity.  
 
ATR gene mutation is associated with Seckel syndrome which is characterised by growth 
retardation and microcephaly. However the role of ATR gene mutations or polymorphisms in 
cancer pathogenesis is less well defined. In breast cancer, no significant associations between 
ATR or Chk1 polymorphism, cancer risk or survival outcomes have been demonstrated. The 
clinical significance of ATR or Chk1 mRNA or protein expression is also not fully known in 
human cancer. Despite a paucity of clinical studies, ATR and Chk1 have emerged as 
promising anti-cancer drug targets. In cell line models, dominant negative inhibition of ATR 
function resulted in hypersensitivity to multiple chemotherapeutic agents and radiation. 
Similarly, ATR or Chk1 knockdown by siRNA lead to chemotherapy and radiotherapy 
potentiation. Pharmacological inhibition of ATR or Chk1 by small molecule inhibitors results 
in chemotherapy and radiotherapy potentiation in cancer cell lines as well as in xenograft 
models. Extensive preclinical data therefore provides compelling evidence to investigate 
ATR and/or Chk1 blockade as a promising therapeutic target in patients. 
 
Our hypothesis is that altered ATR and pChk1 expression may influence breast cancer 
biology and behaviour, adversely impact clinical outcomes and could be suitable for rational 
therapeutic targeting in breast cancer.  In the current study we have investigated ATR and 
Chk1 in large cohorts of primary breast cancers at the protein and mRNA level and have 
demonstrate for the first time that ATR and pChk1 overexpression is linked to aggressive 
phenotype and poor outcomes in breast cancer. Pre-clinically, in breast cancer cell lines we 
show that phosphorylation and activation of Chk1 at Ser345 is ATR dependent. ATR gene 
knockdown or ATR inhibition by small molecule inhibition impairs breast cancer cell 
growth.  We conclude that ATR-pChk1 is a rational target for therapeutic application in 
breast cancer. 
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METHODS 
Clinical study 
Patients: The study was performed in a consecutive series of 1712 patients with primary 
invasive breast carcinoma who were diagnosed from 1986 to 1999 and entered into the 
Nottingham Tenovus Primary Breast Carcinoma series. Patient demographics are 
summarised in supplementary table S1. This is a well-characterized series of patients with 
long-term follow-up that have been investigated in a wide range of biomarker studies {Ellis, 
1992 #32;Ellis, 1992 #32;Elston, 1991 #31}.  All patients were treated in a uniform way in a 
single institution with standard surgery (mastectomy or wide local excision) with 
radiotherapy. Prior to 1989, patients did not receive systemic adjuvant treatment (AT). After 
1989, AT was scheduled based on prognostic and predictive factor status, including 
Nottingham Prognostic Index (NPI), oestrogen receptor-α (ER-α) status, and menopausal 
status. Patients with NPI scores of <3.4 (low risk) did not receive AT. In pre-menopausal 
patients with NPI scores of ≥3.4 (high risk), classical Cyclophosphamide, Methotrexate, and 
5-Flurouracil (CMF) chemotherapy was given; patients with ER-α positive tumours were also 
offered endocrine therapy. Postmenopausal patients with NPI scores of ≥3.4 and ER-α 
positivity were offered endocrine therapy, while ER-α negative patients received classical 
CMF chemotherapy. Median follow up was 111 months (range 1 to 233 months).  Survival 
data, including overall survival, disease-free survival (DFS), and development of loco-
regional and distant metastases (DM), was maintained on a prospective basis.  DFS was 
defined as the number of months from diagnosis to the occurrence of local recurrence, local 
lymph node (LN) relapse or DM relapse.  Breast cancer specific survival (BCSS) was defined 
as the number of months from diagnosis to the occurrence of BC related-death. Local 
recurrence free survival (LRS) was defined the number of months from diagnosis to the 
occurrence of local recurrence. DM-free survival was defined as the number of months from 
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diagnosis to the occurrence of DM relapse.  Survival was censored if the patient was still 
alive at the time of analysis, lost to follow-up, or died from other causes. 
Tumor Marker Prognostic Studies (REMARK) criteria, recommended by McShane et al 
{McShane, 2005 #37}, were followed throughout this study.  Ethical approval was obtained 
from the Nottingham Research Ethics Committee (C202313).  
 
Construction of Tissue Microarray (TMA): TMAs were constructed as previously 
described (refs).. Four micron sections of the tissue array block were cut and placed on 
Superfrost Plus slides for immunohistochemical staining.   
 
Immunohistochemistry (IHC): The TMAs were immunohistochemically profiled for ATR, 
phosphorylated Chk1 and other biomarkers included in this study (Supplementary Table S2) 
as previously described {Sultana, 2013 #4088}. Immunohistochemical staining was 
performed using the Thermo Scientific Shandon Sequenza chamber system (REF: 
72110017), in combination with the Novolink Max Polymer Detection System (RE7280-K: 
1250 tests), and the Leica Bond Primary Antibody Diluent (AR9352), each used according to 
the manufacturer’s instructions (Leica Microsystems).  The tissue slides were deparaffinised 
with xylene and then rehydrated through five decreasing concentrations of alcohol (100%, 
90%, 70%, 50% and 30%) for two minutes each. Pre-treatment antigen retrieval was 
performed on the TMA sections using sodium citrate buffer (pH 6.0), heated for 20 minutes 
at 950C in a microwave (Whirlpool JT359 Jet Chef 1000W). A set of slides were incubated 
for 18 hours at 40C with the primary mouse monoclonal anti-ATR antibody, clone 1E9 
(H00000545-M03, Novus Biologicals, Cambridge, UK), at a dilution of 1:20. A further set of 
slides were incubated for 60 minutes with the primary rabbit polyclonal anti-phosphorylated 
Chk1 antibody (Ab58567, Abcam, Cambridge, UK), at a dilution of 1:140. 
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To validate the use of TMAs for immunophenotyping, full-face sections of 40 cases were 
stained and protein expression levels of DNA-PKcs antibodies were compared.  The 
concordance between TMAs and full-face sections was excellent (k = 0.8). Positive and 
negative (by omission of the primary antibody and IgG-matched serum) controls were 
included in each run.  
 
Evaluation of immunohistochemical staining: The tumour cores were evaluated by 
specialist pathologists and oncologists blinded to the clinico-pathological characteristics of 
patients. Whole field inspection of the core was scored and intensities of nuclear staining 
were grouped as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, 3 = 
strong staining. The percentage of each category was estimated (0-100%).  H-score (range 0-
300) was calculated by multiplying intensity of staining and percentage staining. H-score in a 
range of 0 – 300 was generated. The median H-score of 100 was taken as the cut-off and low 
ATR or pChk1 expression was classed as H-score of ≤ 100 and >100 was classed as high for 
ATR or pChk1 expression.  Not all cores within the TMA were suitable for IHC analysis as 
some cores were missing or lacked tumour. HER2 expression was assessed according to the 
new ASCO/CAP guidelines using IHC and chromogenic in situ hybridisation (CISH) {Wolff, 
2007 #36}. 
 
 
ATR and Chk1 gene expression: The mRNA expression of ATR and Chk1 was performed in 
the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) cohort. 
The METABRIC study protocol, detailing the molecular profiling methodology in a cohort of 
1980 breast cancer samples is described by Curtis et al (Curtis et al.).  Patient demographics 
are summarized in supplementary Table S3 of supporting information. ER positive and/or 
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lymph node negative patients did not receive adjuvant chemotherapy.  ER negative and/or 
lymph node positive patients received adjuvant chemotherapy.  RNA was extracted from 
fresh frozen tumours and subjected to transcriptional profiling on the Illumina HT-12 v3 
platform.  The data was pre-processed and normalized as described previously (Curtis et al.). 
ATR and Chk1 expression was investigated in this data set and correlated with 
clinicopathological features, molecular classes and outcome.  X-tile (version 3.6.1, Yale 
University, USA) was used to identify a cut-off in gene expression values to divide the 
population in to high/low subgroups prior to analysis.  The Chi-square test was used for 
testing association between categorical variables and a multivariate Cox model was fitted to 
the data using as endpoint breast cancer specific death. Cumulative survival probabilities 
were estimated using the Kaplan–Meier method. 
 
Statistical analyses: Data analysis was performed using SPSS (SPSS, version 17 Chicago, 
IL). Where appropriate, Pearson’s Chi-square, Fisher’s exact, 2 for trend, Student’s t and 
ANOVAs one way tests were performed using SPSS software (SPSS, version16 Chicago, 
IL).  Cumulative survival probabilities were estimated using the Kaplan–Meier method. 
Differences between survival rates were tested for significance using the log-rank test.  
Multivariate analysis for survival was performed using the Cox hazard model. The 
proportional hazards assumption was tested using standard log-log plots.  Each variable was 
assessed in univariate analysis as a continuous and categorical variable and the two models 
were compared using an appropriate likelihood ratio test.  Hazard ratios (HR) and 95% 
confidence intervals (95% CI) were estimated for each variable.  All tests were two-sided 
with a 95% CI. P values for each test were adjusted with Benjamini and Hochberg multiple 
P-value adjustment and an adjusted p value of <0.05 was considered significant. 
 
Pre-clinical study 
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Chemicals and reagents: All chemicals and reagents were obtained from Sigma (St Louis, 
MO, USA) unless otherwise stated.  VE-821 was from Vertex Pharmaceuticals (Abingdon, 
UK). 
Cells and cell lines: MCF7 (p53 wild type, ER +ve human breast adenocarcinoma) and 
MDA-MB-231 (p53 mutant, triple negative human breast adenocarcinoma) cells were grown 
in RPMI-1641 media containing 10% FBS, 100 units/ml penicillin and 0.1 mg/ml 
streptomycin.  MCF10A (p53 wild type, immortalised human non-tumorigenic breast 
epithelium) cells  from ATCC (Manassus, VA, USA) were maintained in DMEM/Ham’s F12 
Nutrient mixture with 5% horse serum (Gibco, Life Technologies, Paisley, UK), 0.5 µg/ml 
hydrocortisone, 20 ng/ml epidermal growth factor, 10 µg/ml insulin and 100 ng/ml cholera 
toxin.  Cells were maintained at 37°C and 5% CO2 and were authenticated (LGC Standards, 
Teddington, UK) and confirmed to be mycoplasma free (Mycoalert, Lonza, Basel, 
Switzerland). 
siRNA knockdown of ATR: MCF7 cells were added to either scrambled siRNA (5' –
UUCUCCGAACGUGUCACGUdtdt) or ATR specific siRNA (5’-
CAUCUUAUCCCAUGCGUGUdtdt) diluted in OptiMEM (Gibco, Life Technologies, 
Paisley, UK) and Lipofectamine RNAiMax (Life Technologies, Paisley, UK) to a final 
siRNA concentration of 10 nM. Cells were allowed to adhere for 48 hours before being 
treated for 1 hour with 1 µM gemcitabine or 10 mM hydroxyurea.   
shRNA knockdown of ATR: Lentivirus particles containing ATR-specific shRNA were 
formed by transfecting HEK293T cells with pCMVΔ8.91 packaging vector, pMD2.G 
envelope vector and pTRIPZ doxycycline-inducible lentiviral vector  containing ATR 
shRNA (Thermo, Northumberland, UK).  Virus particles released into the media were 
collected and purified via ultracentrifugation using Lenti-X concentrator (Clontech, Mountain 
View, USA).  MCF7 cells were transduced with ATR shRNA lentivirus and stably 
expressing clones identified and grown by selection using 1 µg/ml puromycin.  MCF7 
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shATR cells were maintained in full media supplemented with 1 µg/ml puromycin.  shATR 
expression was induced by supplementing media with 1 µg/ml doxycycline.  Cells grown in 
the absence of doxycycline were used as a control. 
Gel electrophoresis and western blotting: Cells were prepared for gel electrophoresis by 
lysis using Phosphosafe extraction reagent (Merck, Darmstadt, Germany) and sonication.  
Protein concentration was determined using a Pierce BCA protein assay (Thermo, 
Northumberland, UK).  Lysates were diluted in 4 x XT sample buffer (Bio-Rad, Hemel 
Hempstead, UK) and subjected to gel electrophoresis using 4-15% Tris-Glycine cells (Bio-
Rad, Hemel Hempstead, UK).  Proteins were transferred onto Hybond C-Extra nitrocellulose 
membrane (GE Healthcare, Buckinghamshire, UK) using western blotting.  Proteins were 
detected using primary antibodies incubated overnight at 4°C: goat anti-ATR (1:300 N-19 – 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-pChk1Ser345 (1:300 133D3 – 
Cell Signalling Technologies, Danvers, MA, USA), mouse anti-Chk1 (1:300 G-4 – Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-actin (1:1000 AC40 – Sigma, Poole, 
UK), mouse anti-β-actin (1:10000 2D1D10 – Genscript, Piscataway, NJ, USA).  Secondary 
antibodies were anti-goat-HRP (1:2000, Santa Cruz Technologies, Santa Cruz, CA, USA), 
anti-mouse-HRP (1:2000 – Dako UK Ltd, Ely, UK) and anti-rabbit-HRP (1:1000 – Dako UK 
Ltd, Ely, UK).  Chemiluminescence from ECL Prime detection reagent (GE Healthcare, 
Buckinghamshire, UK) was detected using a G-box (Syngene, Cambridge, UK) and band 
intensities were measured by densitometry using Genetools software (Syngene, Cambridge, 
UK). 
Growth  assay: MCF7, MCF7 shATR or MDA-MB-231 cells were seeded at a density of 
1000 cells/well into 96-well tissue culture plates.  To assess the effect of ATR knockdown on 
cell growth MCF7 shATR cells were treated with 1 µg/ml doxycycline for 3 days prior to 
seeding then growth was measured over the next 11 days in fresh medium.  For growth 
inhibition assays cells were treated for 24 hours with VE-821 then allowed to grow in fresh 
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media for 5 days.  Cells were fixed using Carnoy’s fixative and allowed to dry overnight.  
Cell growth was measured by staining cells with 10 µg/ml DAPI in 0.001% Triton-X-100.  
Cells were solubilised using 10 mM EDTA (pH 2.2) and the fluorescence measured at 460 
nm using a MFX Microtiter Plate Fluorimeter (Dynex Technologies, Chantilly, VA, USA). 
Clonogenic survival assay: MCF7, MDA-MB-231 or MCF10A cells seeded at a density of 
1 x 105 cells/ml.  Following treatment with VE-821 for 24 hours cells were counted and re-
seeded at low density for colony formation.  Colonies were allowed to grow for 2 weeks in 
fresh media before being fixed using Carnoy’s fixative and stained using 1% crystal violet.  
Colonies were counted and the % plating efficiency calculated. 
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RESULTS 
 
ATR and pChk1 protein expression correlate to aggressive breast cancer phenotypes 
ATR: ATR was detected in the nuclei of the tumour cells with no cytoplasmic or 
membranneous expression. High ATR expression was seen in 409/1298 (31.5%) tumours 
compared to 889/1298 (68.5%) tumours that had low/negative ATR expression (Figure 1A) 
(Table 1). High ATR expression was associated with higher stage (p=0.036), higher tumour 
grade (p<0.001) with higher mitotic index (p<0.001) and cellular pleomorphism (p<0.001) 
and lymphovascular invasion (p=0.009) (Table 1). High ATR expression was associated with 
absent/reduced expression  of DNA damage response (DDR) proteins including BRCA1, 
XRCC1, SMUG1 and DNA-PKcs (p<0.05).  High MIB1, TOPO2A and CDK1 and Low Bax 
and MDM2 were more frequently seen in high ATR expressing tumours (p<0.05).  
pChk1: High cytoplasmic pChk1 expression was seen in 672/1712 (39.3%) tumours 
compared to 1040/1712 (60.7%) tumours that had low ATR expression (Figure 1A) (Table 
2). High cytoplasmic pChk1 protein expression was significantly associated with higher 
grade, higher mitotic index, nuclear pleomorphism, histological tumour type and 
lymphovascular invasion (p<0.05). Triple-negative and basal-like phenotypes were more 
likely in high cytoplasmic pChk1 protein expressing tumours (p<0.05).  Absence/reduced 
expression of DDR proteins includingBRCA1, XRCC1, APE1, polβ, but increased 
expression of ATR and DNA-PKcs were also more likely associated with high cytoplasmic  
pChk1 protein expressing tumours (p<0.05). High MIB1, high TOPO2A, high CDK1 and 
low MDM2 was likely in high cytoplasmic pChk1 protein expressing tumours (p<0.05). 
High nuclear pChk1 expression was seen in 264/1712 (15.4%) tumours compared to 
1448/1712 (84.6%) tumours that had low nuclear pChk1 expression (Figure 1A) 
(Supplementary Table S4). In contrast to cytoplasmic expression, low nuclear pChk1 protein 
expression was significantly associated with features of aggressive behaviour including 
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higher grade, higher mitotic index, de-differentiation and nuclear pleomorphism (p<0.05). 
ER-, PR-, AR-, Her-2 positive tumours were more likely in low nuclear pChk1protein 
expressing tumours (p<0.05).  Absence of BRCA1, low XRCC1, low SMUG1, low APE1, 
low SMUG1, low polβ and low DNA-PKcs were also more likely associated with low 
nuclear pChk1 protein expressing tumours (p<0.05). High MIB1, low TOPO2A and low 
MDM2 was likely in low nuclear pChk1 protein expressing tumours (p<0.05).  
ATR-pChk1 combined analysis: The data presented above suggests that differential 
ATR/pChk1 expression may influence breast cancer phenotypes. To evaluate further, we 
performed ATR/pChk1 combined analysis. As shown in supplementary table S5,  tumours 
that had high ATR expression/high cytoplasmic pChk1 expression/low nuclear pChk1 
expression had larger size, higher stage, higher grade, higher mitotic index, de-
differentiation, pleomorphism, HER-2 overexpression, ER-/PR-/AR-, high MIB1, low 
TOP2A, low Bax and high CDK1 phenotypes (p<0.05). In addition, such tumours also 
exhibited a genomic instability phenotype characterised by absence of BRCA1, low XRCC1, 
low SMUG1, low polβ and low DNA-Pkcs expression (p<0.01). Interestingly, although there 
was no association with p53 mutation, low MDM2 was more likely in tumours with high 
ATR expression/high cytoplasmic pChk1 expression/low nuclear pChk1 expressing tumours. 
ATR and pChk1 protein expression associate with poor survival outcomes in patients 
Univariate analysis: High ATR expression was associated with worse breast cancer specific 
survival in patients (p=0.001) (Figure 1B1). High cytoplasmic pChk1 expression was 
associated with shorter BCSS (p=0.005) (Figure 1B2). In contrast, low nuclear pChk1 
expression was associated with worse BCSS (p=0.007) (Supplementary Figure 1A). 
Investigating nuclear and cytoplasmic pChk1 together we found that patients whose tumours 
have low nuclear and high cytoplasmic Chk1 have the worst survival compared to tumours 
that have high nuclear and low cytoplasmic Chk1 (p<0.001) (Figure 1B3). We then combined 
ATR and pChk1 in the analysis. As shown in figure 1B3, high ATR/low nuclear Chk1/high 
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cytoplasmic Chk1 tumours have the worst survival (p<0.001). As p53 may be involved in the 
activation of ATR-Chk1 pathway we also conducted an exploratory analysis in p53 mutant 
and proficient tumours. As shown in Figures 2A and 2B, high ATR/p53 mutants, high 
cytoplasmic pChk1/p53 mutants have the worst survival compared to tumours that are p53 
wild-type. Similarly, high nuclear pChk1/p53 mutants have the worst survival compared to 
tumours that are p53 wild-type (Supplementary Figure 1B).   
We then proceeded to various sub-group analysis in ER+ and ER- breast cancer cohorts 
(Supplementary Figures 2 and 3). In patients with ER-negative tumours that received no 
chemotherapy, high ATR remains associated with poor survival (Supplementary Figures 
2A1) but this association was not observed in the ER-negative tumours that received adjuvant 
chemotherapy. On the other hand, in ER- negative tumours that received adjuvant 
chemotherapy (anthracycline or CMF chemotherapy), cytoplasmic pChk1 was associated 
with poor survival. Interestingly, whereas, high cytoplasmic pChk1 was associated with poor 
survival after CMF chemotherapy (Supplementary Figures 2B3), low cytoplasmic pChk1 was 
associated with poor survival after anthracycline chemotherapy (Supplementary Figures 
2B2). Nuclear pChk1 did not influence survival in various sub-groups (Supplementary 
Figures 2C). In ER+ tumours, no significance was evident except for nuclear pChk1, where 
low expression was associated with poor survival to adjuvant endocrine therapy 
(Supplementary Figures 3).  
Multivariate analysis: High ATR was an independent predictor of worse BCSS in 
multivariate analysis (p=0.006) (Supplementary table S6). Stage, grade, endocrine therapy, 
bcl-2 expression status were other independent markers of poor survival in patients. The 
expression of cytoplasmic or nuclear Chk1 did not independently influence survival. 
ATR and Chk1 mRNA expression in breast cancer 
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The data presented above provides evidence that high ATR and high Chk1 protein expression 
have prognostic significance in breast cancer. To investigate whether RNA of these genes are 
also associated with outcome and to assess the role of RNA-protein translation on the clinical 
signaificance of genes, , we explored ATR and Chk1 mRNA expression in the METABRIC 
cohort that comprises 1950 breast tumours (nature reference).  
Interestingly, high ATR mRNA was not significantly associated with any clinicopathological 
features or survival in the METABRIC cohort (Figure 2B, Supplementary Table S7, 
supplementary Figure 3A and supplementary Figure 3C). On the other hand, as shown in 
supplementary table S8, high Chk1 mRNA was significantly associated with high tumour T-
stage, high grade, lymph node positivity, high risk NPI score (>3.4), HER-2 over expression, 
ER negative, triple negative, and molecular classes associated with aggressive behaviour and 
poor outcome including Genefu subtypes (ER-/Her-2 negative, ER+/Her-2 negative/high 
proliferation), PAM50.Her-2, PAM50. Basal, integrative molecular cluster (intClust).1, 
intClust.5, intClust.9 and intClust.10 phenotypes (p<0.01). Patients with tumours that had 
high Chk1 mRNA had significantly shorter BCSS compared to tumours that had low Chk1 
mRNA expression (p<00001) (Figure 2C). In ER+ tumours that received adjuvant endocrine 
therapy, high Chk1 mRNA was significantly associated with worse BCSS (p<0.001) 
(Supplementary Figure 3B). Conversely, in ER- tumours that received adjuvant 
chemotherapy, high Chk1 mRNA was not associated with worse BCSS (Supplementary 
Figure 3D).  
Taken together, protein as well as mRNA expression data suggests that for ATR, protein over 
expression is likely to be due to a post-transcriptional/translational mechanism. However for 
Chk1, protein over expression is due to transcriptional up-regulation.   
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Replication stress induced phosphorylation of Chk1 at serine345 is ATR dependent in 
breast cancer cells 
Multivariate analysis in human tumours provides evidence that ATR independently 
influences survival in patients and is key biomarker. To provide further preclinical evidence 
we proceeded to mechanistic studies in breast cancer cell lines. We first generated ATR 
knockdown (KD) breast cancer cells using an ATR specific siRNA construct. As shown in 
Figure 3A1 and 3A2, we achieved more than 90% KD of ATR in MCF7 cells. To induce 
replication stress, ATR wild type or ATR KD MCF7 cells were treated with 1μΜ of 
gemcitabine or 10 mM of hyroxydyurea (HU). Phosphorylation of Chk1 at serine345 was 
impaired, upon gemcitabine or HU treatment, in ATR KD cells but not in MCF7 cells treated 
with scrambled control (Figure 3A1 and 3A2). The data shows that Chk1 phosphorylation is 
ATR dependent in breast cancer cells. To provide further evidence, we treated MCF7 with 
VE-821, a potent and selective ATP competitive inhibitor of ATR (Ki and IC50 of 13 nM and 
26 nM respectively). Whereas gemcitabine treatment in the absence of VE-821 induced 
robust phosphorylation of Chk1 at serine345, there was a dose dependent inhibition of Chk1 
phosphorylation by VE-821 in Gemcitabine treated cells (Figures 3B1-3) [IC50 (μM): MCF7 
= 3.62 ± 1.94, MDA-MB-231 = 0.57 ± 0.30]. In MDA-MD-231 and in non-tumorigenic 
breast epithelium cells (MC710A) we also observed a similar impairment of Chk1 
phosphorylation by VE-821 (Figures 3B2 and 3B3) (IC50 (μM) = 1.16 ± 1.32). Taken 
together the data confirms that Chk1 activation is ATR dependent in MCF7, MDA-MB-231 
and MCF10A cells.    
ATR is required for breast cancer cell growth 
To investigate whether ATR depletion has biological consequences in cells, we generated 
stable ATR KD MCF7 cells using doxycycline inducible shRNA. Following 3 days of 
treatment with doxycycline, robust KD of ATR was evident (Figure 4A1). Doxycycline was 
then removed and cell were monitored for growth and ATR protein expression over 11 days. 
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As shown in Figure 4A1 and 4A2, ATR deficiency arrested cell growth. However upon re-
expression of ATR, cell growth was restored. Doxycycline treatment alone in un-transfected 
MCF7 cells had no effect (supplementary Figure 4). 
We then investigated the effect of VE-821 in breast cancer cells. As shown in Figure 4B, a 
dose dependent suppression of cell growth was evident in MCF7 (GI50 = 0.25 μM) and in 
MDA-MB-231 cells (GI50 = 1.70 μM). There was also a significant direct correlation 
between growth inhibition and ATR inhibition in MCF7 and MDA-MB-231 cells (Figure 
4C).  To investigate whether VE-821 has selective toxicity to cancer cells, we performed 
clonogenic cell survival assays in MCF7, MDA-MB-231 and MCF10A cells. VE-821 
exhibited selective toxicity in breast cancer cells (MCF7 and MDA-MB-23) compared to 
non-tumorigenic breast epithelium cells (MCF10A) (Figure 4D).  
Taken together the preclinical study provides evidence that ATR is essential for breast cancer 
growth. In addition, the data also concurs with clinical study that demonstrated ATR 
overexpression as an independent prognostic factor in breast cancer.  
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DISCUSSION 
ATR, a key factor in the maintenance of genomic integrity, is activated by single stranded 
(ss)-double stranded (ds) DNA junctions generated at stalled replication forks either during 
replication stress or during genotoxic therapy. Activated ATR in turn phosphorylates Chk1 at 
Ser 345 (pChk1) resulting in regulation of cell cycle progression and DNA repair. This is the 
first study to comprehensively investigate ATR and pChk1 in large cohorts of breast cancers. 
The data presented here provides compelling evidence that ATR and pChk1 have prognostic 
and predictive significance in breast cancer.  
Chk1 is a key mediator of checkpoint regulation, genomic stability and cellular survival. 
Emerging evidence suggests that Chk1 undergoes alterations in sub-cellular localisation in 
response to DNA damage. Under normal conditions, Chk1 is localized to the nucleus. Upon 
DNA damage, ATR induced phosphorylation of Chk1 results in rapid localization to the 
cytoplasm. Nuclear Chk1 is known to activate RAD-51 dependent DNA repair whereas 
cytoplasmic Chk1 may be involved in cytoplasmic downstream checkpoint events. Chk1 
phosphorylated at serine 345 is known to accumulate in the cytoplasm (Naidi et al JCB).  To 
address whether cytoplasmic or nuclear pChk1 has clinicopathological significance in breast 
cancer, we evaluated pChk1 expression in the nucleus as well as in the cytoplasm of breast 
tumour cells. The data presented here provides evidence that over expression of cytoplasmic 
pChk1 is associated with aggressive features such as high grade, higher mitotic index 
including association with high MIB1, pleomorphism, triple negative, basal-like phenotype 
and poor survival. The data would concur with preclinical observation that suggest a genomic 
instability phenotype for cells that sequester Chk1 in the cytoplasm thereby driving a mutator 
phenotype characterised by aggressive pathology and clinical behaviour. Interestingly, 
nuclear pChk1 overexpression appears to be associated with lower grade, lower mitotic 
index, better differentiated tumours and improved survival in our study. Moreover, nuclear 
pChk1 overexpressing tumours are likely to be ER positive and associate with high 
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expression of other DNA repair proteins such as BRCA1, XRCC1, FEN1, SMUG1, APE1, 
polymerase beta and DNA-PKcs. The data would concur with preclinical observations 
suggesting a genomic stability role for nuclear Chk1. Combined analysis also showed that 
tumours with high cytoplasmic/low nuclear pChk1 tumours have the worst survival compared 
with low cytoplasmic/high nuclear tumours implying  that altered sub-cellular localisation of 
Chk1 has clinicopathological significance. A striking observation in the current study was 
that Chk1 mRNA overexpression was very highly significantly associated with aggressive 
phenotypes (such as lymph node positivity, high grade, high risk NPI score, ER+ luminal 
phenotype, Her-2 overexpression, triple negative phenotype) and poor survival. Chk1 mRNA 
levels were also linked to biologically distinct integrative clusters reported in the 
METABRIC study. High Chk1 mRNA level was frequent in intClust 10 subgroup which is 
the most highly genomically instable sub group with basal-like features.  Whereas low Chk1 
mRNA level was seen in intClust 3 subgroup that is characterised by low genomic instability. 
In addition, high Chk1 mRNA level is also frequently seen in intClust 5 (HER-2 enriched 
with worst survival), intClust 9 (8q cis-acting/20qamplified mixed subgroup), and intClust 1 
(17q23/20q cis-acting luminal B subgroup) subgroups that also manifest an aggressive 
phenotype. On the other hand, low Chk1 mRNA level is linked to intClust 4 (includes both 
ER-positive and ER-negative cases with a flat copy number landscape and termed the ‘CNA-
devoid’ subgroup with extensive lymphocytic infiltration), intClust 7 (16p gain/16q loss with 
higher frequencies of 8q amplification luminal A subgroup) and intClust 8 subgroups 
(classical 1q gain/16q loss luminal A subgroup) (18).  High Chk1 mRNA was associated with 
poor survival in the METABRIC cohort. Interestingly, intClust 10, intClust 9, intClust 5 and 
intClust 1 sub-groups that are associated with high Chk1 levels were also associated with 
poor prognosis in METABRIC study (18).In contrast, intClust 3, intClust 4, intClust 7 and 
intClust 8 that are associated with low Chk1 expression, are associated with good to 
intermediate prognosis. In a study in triple negative breast cancer, Chk1was found to be 
overexpressed by transcriptional up-regulation through E2F1 Transcription factor. Similarly, 
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in lung cancer and colorectal cancer high levels of Chk1 may be associated with poor 
differentiation and worse survival. Together the data provides further evidence that Chk1 is a 
key biomarker and a rational drug target in breast cancer.  
A surprising observation in the METABRIC cohort was that ATR mRNA expression was not 
associated with any adverse clinicopathological features or survival implying that ATR 
protein overexpression is likely due to post-transcriptional/translational mechanisms.  ATR 
protein overexpression was associated with aggressive tumours (such as high grade, size, 
higher mitotic index, pleomorphism) and poor survival. As proficient ATR and pChk1 
indicate a functional ATR-Chk1 signalling pathway in cells, we performed combined 
analysis and demonstrated that tumours that are high ATR/high cytoplasmic pChk1/low 
nuclear Chk1 have the most aggressive phenotype and the worst survival.  
Preclinical studies provide a link between p53 and ATR-Chk1 network. Loss of p53 may lead 
to increased replication stress and influence ATR/Chk1 expression. Interestingly, p53 
deficient tumours appear to be sensitive to blockade by ATR or Chk1 inhibitors. In the 
current study, although there was no association with p53 mutation, low MDM2 was more 
likely in tumours with high ATR expression/ high cytoplasmic pChk1 expression /low 
nuclear pChk1 expressing tumours.  We also demonstrate that ATR high/p53 mutants and 
Chk1 high/p53 mutants have the worst survival compared to that ATR low/p53 wild type and 
Chk1 high/p53 wild type. The data suggests that such breast cancer would be particularly 
suitable for personalized therapy.  
An unexpected finding in the current study was a lack of clear evidence for predictive 
significance of ATR or Chk1 in breast cancer patients receiving adjuvant chemotherapy. At 
the mRNA level ATR or Chk1 , did not influence survival in ER- negative tumours receiving 
chemotherapy. At the protein level, only cytoplasmic pChk1 overexpression appears to be 
associated with worse survival in patients treated with CMF (cyclophosphamide, 
methotrexate and 5-fluorouracil) chemotherapy. Surprisingly, low cytoplasmic pChk1 was 
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associated with poor survival in patients receiving anthracycline chemotherapy. This is in 
contrast to previous pre-clinical observation suggesting anthracycline sensitivity in Chk1 
deficient cancer cell lines. Therefore further clinical studies are required to confirm these 
observations.   
In the multivariate model, high ATR expression was independently associated with worse 
BCSS implying that ATR is an important prognostic biomarker in breast cancer. To provide 
additional evidence, we investigated in breast cancer cell lines. Firstly, we showed that ATR 
was directly involved in phosphorylation of Chk1 at serine 345 in breast cancer cells. 
Secondly, ATR knock down reduced proliferation and survival. Thirdly, VE-821, a specific 
and potent small molecule inhibitor of ATR not only blocked ATR induced Chk1 
phosphorylation but also reduced breast cancer cell survival in a dose dependent manner. 
Taken together, the clinical and pre-clinical data provides compelling evidence that ATR is a 
promising target for anti-cancer therapy.  
In conclusion, we provide confirmatory evidence that ATR-Chk1 influences breast cancer 
pathogenesis and clinical outcomes. Our data would support accelerated evaluation of ATR 
and Chk1 inhibitors currently under clinical development for personalized therapy in breast 
cancer patients.   
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TABLES 
Table 1. ATR protein expression in breast cancer. 
   
 
                    VARIABLE 
 
ATR PROTEIN EXPRESSION 
                   
 
 
P- value 
       Low 
N (%) 
 
      High 
N (%) 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
96 (10.8) 
476 (53.5) 
296 (33.3) 
21 (2.4) 
 
32 (7.8) 
178 (43.5) 
187 (45.7) 
12 (2.9) 
 
1.6x10-4 
Tumour Stage                                 
1 
2 
3 
 
 
577 (64.8) 
241 (27.1) 
72 (8.1) 
 
236 (57.4) 
133 (32.4) 
42 (10.2) 
 
0.036 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
175 (19.7) 
295 (33.2) 
419 (47.1) 
 
39 (9.5) 
112 (27.4) 
258 (63.1) 
 
1.0x10-5 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
338 (38.3) 
160 (18.1) 
384 (43.5) 
 
97 (23.7) 
73 (17.8) 
239 (58.4) 
 
1.0x10-5 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
62 (7.0) 
287 (32.5) 
533 (60.4) 
 
15 (3.7) 
135 (33.0) 
259 (63.3) 
 
0.058 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
30 (3.4) 
361 (41.0) 
489 (55.6) 
 
3 (0.7) 
117 (28.6) 
289 (70.7) 
 
1.0x10-5 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
449 (58.2) 
164 (21.2) 
26 (3.4) 
65 (8.4) 
68 (8.8) 
 
223 (65.6) 
58 (17.1) 
5 (1.5) 
21 (6.2) 
33 (9.7) 
 
0.061 
Lymphovascular Invasion                   
No 
Yes 
 
606 (69.0) 
272 (31.0) 
 
252 (61.6) 
157 (38.4) 
 
0.009 
B) Aggressive phenotype 
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Her2 overexpression                     
No 
Yes 
 
775 (89.0) 
96 (11.0) 
 
348 (87.0) 
52 (13.0) 
 
0.307 
Triple Negative Phenotype               
No 
Yes 
 
702 (81.1) 
162 (18.8) 
 
326 (81.1) 
76 (18.9) 
 
0.947 
Basal Like Phenotype           
No 
Yes 
 
731 (86.9) 
110 (13.1) 
 
340 (88.3) 
45 (11.7) 
 
0.496 
Cytokeratin 6 (CK6)                                  
Negative 
Positive 
618 (82.1) 
135 (17.9) 
 
285 (86.4) 
45 (13.6) 
 
0.081 
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive 
641 (85.6) 
108 (14.4) 
292 (89.3) 
35 (10.7) 
 
0.099 
Cytokeratin 18 (CK18)                                   
Negative 
Positive 
75 (11.0) 
607 (89.0) 
 
 
36 (11.5) 
277 (88.5) 
 
0.814 
Cytokeratin 19 (CK19)                                   
Negative 
Positive 
42 (5.6) 
708 (94.4) 
 
25 (7.6) 
302 (92.4) 
 
0.201 
ATF2 
Low 
High 
 
335 (51.5) 
315 (48.5) 
 
141 (43.7) 
182 (56.3) 
 
0.020 
C) Hormone receptors 
 
ER               
Negative 
Positive 
 
231 (26.5) 
642 (73.5) 
 
114 (27.9) 
295 (72.1) 
 
0.595 
PgR                                   
Negative 
Positive 
 
357 (43.2) 
469 (56.8) 
 
165 (43.5) 
214 (56.5) 
 
0.918 
AR                     
Negative 
Positive 
 
 
266 (38.1) 
432 (61.9) 
 
120 (37.9) 
197 (62.1) 
 
0.938 
D) DNA Repair 
 
27 
 
BRCA1                     
Absent 
 Normal 
 
114 (19.2) 
479 (80.8) 
 
63 (21.5) 
230 (78.5) 
 
0.425 
XRCC1                             
Low 
High 
 
101 (16.3) 
520 (83.7) 
 
48 (15.7) 
258 (84.3) 
 
0.822 
FEN1(Nuclear)                   
Low 
High 
 
443 (74.5) 
152 (25.5) 
 
205 (72.4) 
78 (27.6) 
 
0.526 
SMUG1                  
Low 
High 
 
 
189 (34.9) 
353 (65.1) 
 
 
122 (43.7) 
157 (56.3) 
 
0.013 
APE1 
Low 
High 
 
400 (55.2) 
325 (44.8) 
 
151 (41.3) 
215 (58.7) 
 
1.4x10-5 
PolB 
Low 
High 
 
 
298 (38.8) 
470 (61.2) 
 
140 (37.2) 
236 (62.8) 
 
0.608 
DNA-PK  
Low 
High 
 
274 (39.0) 
428 (61.0) 
 
113 (30.5) 
257 (69.5) 
 
0.006 
E) Cell cycle/apoptosis regulators 
 
P16 
Low 
High 
 
521 (86.1) 
84 (13.9) 
 
243 (86.5) 
38 (13.5) 
 
0.885 
P21 
Low 
High 
 
379 (58.4) 
270 (41.6) 
 
153 (55.0) 
125 (45.0) 
 
0.343 
MIB1                       
Low 
High 
 
377 (52.5) 
341 (47.5) 
 
112 (31.8) 
240 (68.2) 
 
1.0x10-5 
P53              
Low expression 
High expression 
           
 
559 (78.5) 
153 (21.5) 
 
257 (79.3) 
67 (20.7) 
 
0.768 
Bcl-2                            
Negative 
Positive 
 
284 (35.5) 
517 (64.5) 
 
126 (36.3) 
221 (63.7) 
 
0.781 
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TOP2A                    
Low 
Overexpression 
 
 
295 (48.6) 
312 (51.4) 
 
118 (37.9) 
193 (62.1) 
 
0.002 
Phospho-Chk1 (cytoplasmic)  
Low 
High 
 
272 (30.6) 
618 (69.4) 
 
74 (17.8) 
341 (82.2) 
 
1.0x10-6 
Phospho-Chk1 (Nuclear)                            
Low 
High 
 
731 (82.1) 
159 (17.9) 
 
351 (84.6) 
64 (15.4) 
 
0.275 
Bax                         
Low 
High 
 
329 (66.7) 
164 (33.3) 
 
177 (75.0) 
59 (25.0) 
 
0.023 
CDK1                            
Low 
High 
 
390 (75.0) 
130 (25.0) 
 
190 (62.9) 
112 (37.1) 
 
2.5x10-4 
MDM2                          
Low 
Overexpression 
 
449 (72.9) 
167 (27.1) 
 
219 (79.6) 
56 (20.4) 
 
0.032 
Bold= statistically significant; BRCA1: Breast cancer 1, early onset; HER2: human 
epidermal growth factor receptor 2; ER: oestrogen receptor; PgR: progesterone receptor; CK: 
cytokeratin; Basal-like: ER-, HER2 and positive expression of either CK5/6, CK14 or EGFR; 
Triple negative: ER-/PgR-/HER2- 
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Table 2. Cytoplasmic pChk1 expression in breast cancer. 
   
 
                    VARIABLE 
 
pCHK1 (Cyto) PROTEIN 
EXPRESSION 
                   
 
 
P- value 
       Low 
N (%) 
 
      High 
N (%) 
A) Pathological    Parameters 
Tumour Size  
 <1cm 
 >1-2cm 
 >2-5cm 
>5cm 
 
93 (13.8) 
342 (50.9) 
219 (32.6) 
18 (2.7) 
 
107 (10.3) 
520 (50.0) 
388 (37.3) 
25 (2.4) 
 
0.067 
Tumour Stage                                 
1 
2 
3 
 
 
445 (66.1) 
183 (27.2) 
45 (6.7) 
 
634 (60.8) 
304 (29.1) 
105 (10.1) 
 
0.021 
Tumour Grade                              
 G1 
 G2 
 G3 
  
 
131 (19.5) 
226 (33.6) 
315 (46.9) 
 
166 (16.0) 
339 (32.6) 
535 (51.4) 
 
0.091 
Mitotic Index  
M1 (low; mitoses < 10) 
M2 (medium; mitoses 10-18) 
M3 (high; mitosis >18) 
 
271 (40.8) 
113 (17.0) 
280 (42.2) 
 
349 (33.7) 
200 (19.3) 
487 (47.0) 
 
0.012 
Tubule Formation                          
1 (>75% of definite tubule) 
2 (10%-75% definite tubule) 
3 (<10% definite tubule) 
 
41 (6.2) 
213 (32.1) 
410 (61.7) 
 
60 (5.8) 
346 (33.4) 
630 (60.8) 
 
0.830 
Pleomorphism                                
1 (small-regular uniform) 
2 (Moderate variation) 
3 (Marked variation) 
 
21 (3.2) 
279 (42.1) 
363 (54.8) 
 
23 (2.2) 
382 (36.9) 
630 (60.9) 
 
0.034 
Tumour Type                
IDC-NST 
Tubular Carcinoma 
Medullary Carcinoma 
ILC 
Others 
 
304 (55.1) 
117 (21.2) 
18 (3.3) 
69 (12.5) 
44 (8.0) 
 
546 (60.6) 
1376 (19.5) 
20 (2.2) 
76 (8.4) 
83 (9.2) 
 
0.041 
Lymphovascular Invasion                   
No 
Yes 
 
473 (71.0) 
193 (29.0) 
 
676 (65.8) 
351 (34.2) 
 
0.025 
B) Aggressive phenotype 
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Her2 overexpression                     
No 
Yes 
 
580 (89.2) 
70 (10.8) 
 
895 (88.2) 
120 (11.8) 
 
0.510 
Triple Negative Phenotype               
No 
Yes 
 
548 (84.3) 
102 (15.7) 
 
811 (80.0) 
203 (20.0) 
 
0.026 
Basal Like Phenotype           
No 
Yes 
 
576 (91.9) 
51 (8.1) 
 
846 (86.0) 
138 (14.0) 
 
4.1x10-5 
Cytokeratin 6 (CK6)                                  
Negative 
Positive 
453 (85.0) 
80 (15.0) 
 
726 (83.0) 
149 (17.0) 
 
0.319 
Cytokeratin 14 (CK14)                                                                     
Negative 
Positive 
461 (86.8) 
70 (13.2) 
757 (87.2) 
111 (12.8) 
 
0.831 
Cytokeratin 18 (CK18)                                   
Negative 
Positive 
52 (10.5) 
441 (89.5) 
 
 
87 (10.8) 
720 (89.2) 
 
0.895 
Cytokeratin 19 (CK19)                                   
Negative 
Positive 
37 (6.9) 
500 (93.1) 
 
53 (6.1) 
810 (93.9) 
 
0.579 
ATF2 
Low 
High 
 
259 (55.3) 
209 (44.7) 
 
359 (46.0) 
422 (54.0) 
 
0.001 
C) Hormone receptors 
 
ER               
Negative 
Positive 
 
158 (23.9) 
503 (76.1) 
 
288 (28.0) 
739 (72.0) 
 
0.060 
PgR                                   
Negative 
Positive 
 
246 (40.3) 
364 (59.7) 
 
420 (43.5) 
545 (56.5) 
 
0.211 
AR                     
Negative 
Positive 
 
 
180 (36.4) 
314 (63.6) 
 
298 (36.3) 
522 (63.7) 
 
0.972 
D) DNA Repair 
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BRCA1                     
Absent 
 Normal 
 
68 (15.9) 
360 (84.1) 
 
150 (20.6) 
579 (79.4) 
 
0.049 
XRCC1                             
Low 
High 
 
72 (16.4) 
366 (83.6) 
 
108 (14.5) 
639 (85.5) 
 
0.359 
FEN1                   
Low 
High 
 
319 (75.1) 
106 (24.9) 
 
495 (71.0) 
202 (29.0) 
 
0.141 
SMUG1                  
Low 
High 
 
 
157 (38.8) 
248 (61.2) 
 
 
238 (36.6) 
412 (63.4) 
 
0.483 
APE1 
Low 
High 
 
264 (65.3) 
140 (34.7) 
 
389 (43.8) 
500 (56.2) 
 
1.0x10-5 
PolB 
Low 
High 
 
 
242 (50.9) 
233 (49.1) 
 
295 (31.9) 
630 (68.1) 
 
1.0x10-5 
ATR  
Low 
High 
 
272 (78.6) 
74 (21.4) 
 
618 (64.4) 
341 (35.6) 
 
1.0x10-6 
DNA-PK  
Low 
High 
 
159 (52.1) 
146 (47.9) 
 
252 (29.0) 
616 (71.0) 
 
1.0x10-5 
E) Cell cycle/apoptosis regulators 
 
P16 
Low 
High 
 
364 (86.1) 
59 (13.9) 
 
607 (87.1) 
90 (12.9) 
 
0.621 
P21 
Low 
High 
 
255 (56.9) 
193 (43.1) 
 
425 (57.6) 
313 (42.4) 
 
0.821 
MIB1                       
Low 
High 
 
220 (41.6) 
309 (58.4) 
 
299 (34.0) 
580 (66.0) 
 
0.004 
P53              
Low expression 
High expression 
           
 
409 (81.2) 
95 (18.8) 
 
663 (78.0) 
187 (22.0) 
 
0.168 
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Bcl-2                            
Negative 
Positive 
 
189 (32.6) 
390 (67.4) 
 
337 (36.3) 
591 (63.7) 
 
0.146 
TOP2A                    
Low 
Overexpression 
 
 
227 (50.4) 
223 (49.6) 
 
305 (42.2) 
418 (57.8) 
 
0.006 
pCHK1 (Nuclear)                       
Low 
High 
 
642 (95.1) 
33 (4.9) 
 
813 (77.7) 
233 (22.3) 
 
1.0x10-5 
Bax                         
Low 
High 
 
216 (66.9) 
107 (33.1) 
 
423 (70.6) 
176 (29.4) 
 
0.240 
CDK1                            
Low 
High 
 
202 (75.1) 
67 (24.9) 
 
457 (68.6) 
209 (31.4) 
 
0.049 
MDM2                          
Low 
Overexpression 
 
294 (70.8) 
121 (29.2) 
 
552 (77.2) 
163 (22.8) 
 
0.018 
BRCA1: Breast cancer 1, early onset; HER2: human epidermal growth factor receptor 2; ER: 
oestrogen receptor; PgR: progesterone receptor; CK: cytokeratin; Basal-like: ER-, HER2 and 
positive expression of either CK5/6, CK14 or EGFR; Triple negative: ER-/PgR-/HER2- 
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FIGURE LEGENDS 
Figure 1. ATR and pChk1 protein expression in breast cancer. A.  Microphotograph of ATR 
and pChk1 negative positive breast cancer tissue.  B. Kaplan Meier curves showing breast 
cancer specific survival (BCSS) and ATR expression (B1). Kaplan Meier curves showing 
breast cancer specific survival (BCSS) and cytoplasmic pChk1 expression (B2). Kaplan 
Meier curves showing breast cancer specific survival (BCSS) and nuclear pChk1 expression 
(B3). Kaplan Meier curves showing breast cancer specific survival (BCSS) and combined 
nuclear/cytoplasmic pChk1 expression (B4).  Kaplan Meier curves showing breast cancer 
specific survival (BCSS) and combined ATR/ pChk1 expression (B5). 
Figure 2. A. Kaplan Meier curves showing breast cancer specific survival (BCSS) and 
combined p53/ATR expression (A1). Kaplan Meier curves showing breast cancer specific 
survival (BCSS) and combined p53/cytoplasmic pChk1 expression expression (A2). Kaplan 
Meier curves showing breast cancer specific survival (BCSS) and combined p53/nuclear 
pChk1 expression (A2). B. Kaplan Meier curves showing breast cancer specific survival 
(BCSS) and ATR mRNA expression. C. Kaplan Meier curves showing breast cancer specific 
survival (BCSS) and Chk1 mRNA expression. 
Figure 3. A.  ATR is responsible for Chk1 phosphorylation at serine 345 following 
replication stress. A1. MCF7 cells were subjected to 10 nM siRNA for 48 hours before being 
treated with 1 µM gemcitabine (Gem) or 10 mM hydroxyurea (HU) for 1 hour.  Cells were 
harvested, lysed and the proteins separated using gel electrophoresis.  ATR, pChk1Ser345 and 
β-actin were detected using western blotting.  Bands were quantified using densitometry (A2 
and A3). See text for details. B. VE-821 inhibits gemcitabine-induced ATR activity as 
measured by pChk1Ser345. MCF7, MDA-MB-231 or MCF10A cells were treated with 1 µM 
gemcitabine ± VE-821 for one hour before being harvested and lysed.  Proteins were 
separated and detected using western blotting.  Blot shown is in MDA-MB-231 cells and is 
representative of all experiments (B1).  Concentration-response curve (B2) data shown is the 
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mean ± standard deviation of three individual experiments in each cell line. IC50 values from 
the 3 independent experiments are shown in B3. 
Figure 4. ATR is required for cell growth in MCF7 cells. Cells with doxycyclin (Dox) –
inducible shATR were incubated with or without Dox for 3 days. Then Dox was removed 
and cells were cultured for further indicated days. Cell growth was analysed using DAPI 
fluorescence (A1). ATR expression was monitored by western blotting (A2). Knockdown of 
ATR following Dox induction suppressed growth, which was restored when ATR was re-
expressed.  B. ATR inhibitor VE-821 reduces breast cancer cell growth. MCF7 or MDA-MB-
231 were treated for 24 hours with a dose range of VE-821.  Cells were then allowed to grow 
for 5 days in fresh media.  Cell growth was measured by DAPI fluorescence. C. There was a 
direct correlation between growth inhibition and ATR inhibition in MCF7 and MDA-MB-
231 cells. D. VE-821 is selective against breast cancer cells compared to non-cancer cells. 
MCF7, MDA-MB-231 and MCF10A cells were seeded into 6-well tissue culture plates and 
allowed to adhere for 24 hours.  Cells were treated with VE-821 for 24 hours before being 
counted and re-seeded for colony formation.  Cells were then allowed to grow for 14 days.  
Colonies were then fixed, stained and counted. 
 
 
 
 
 
